Indication: Leukemia

A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.

Relapsed/Refractory Acute Myeloid Leukemia

Sub-indication: AML with FLT3

Line of Therapy: second line

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: AbbVie

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.